{"id":"https://openalex.org/W2936989178","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19019","title":"Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non\u2013small cell lung cancer (NSCLC).","display_name":"Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non\u2013small cell lung cancer (NSCLC).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2936989178","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19019","mag":"2936989178"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.e19019","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19019","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19019","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090256464","display_name":"Corey Jay Langer","orcid":"https://orcid.org/0000-0002-8483-6811","observed_orcids":["https://orcid.org/0000-0002-8483-6811"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey J. Langer","raw_affiliation_strings":["Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103741547","display_name":"Antoinette J. Wozniak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090317","display_name":"The Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800590384","https://openalex.org/I4210090317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antoinette J. Wozniak","raw_affiliation_strings":["Karmanos Cancer Institute, Detroit, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karmanos Cancer Institute, Detroit, MI","institution_ids":["https://openalex.org/I4210090317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Socinski","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Larry Leon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Leon","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shiyao Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shiyao Liu","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089764941","display_name":"Sebastien J. Hazard","orcid":"https://orcid.org/0000-0001-5740-1188","observed_orcids":["https://orcid.org/0000-0001-5740-1188"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sebastien Hazard","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088178599","display_name":"Suresh S. Ramalingam","orcid":"https://orcid.org/0000-0002-0757-3106","observed_orcids":["https://orcid.org/0000-0002-0757-3106"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suresh S. Ramalingam","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"e19019","last_page":"e19019"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8690999746322632,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8690999746322632,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.11159999668598175,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.007899999618530273,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.9539999961853027},{"id":"https://openalex.org/keywords/post-progression-survival","display_name":"post-progression survival","score":0.9679999947547913},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.878000020980835},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7179999947547913},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7459999918937683},{"id":"https://openalex.org/keywords/carboplatin-paclitaxel","display_name":"carboplatin-paclitaxel","score":0.9150000214576721},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7400000095367432},{"id":"https://openalex.org/keywords/landmark-analysis","display_name":"landmark analysis","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.844260573387146},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.656008243560791},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6433408856391907},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6382861137390137},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.47002530097961426},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4554729759693146},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4552518129348755},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44817695021629333},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.43971893191337585},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.42606621980667114},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.41025155782699585},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3905925154685974},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.17766299843788147}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.e19019","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19019","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19019","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3000489420","https://openalex.org/W2230480797","https://openalex.org/W2111815439","https://openalex.org/W1994651154","https://openalex.org/W2105595798","https://openalex.org/W2891670649","https://openalex.org/W2946863839","https://openalex.org/W2042865908","https://openalex.org/W4292496268","https://openalex.org/W2892220650"],"abstract_inverted_index":{"e19019":[0],"Background:":[1],"In":[2,21],"oncologic":[3],"trials,":[4,52],"it":[5],"is":[6],"common":[7],"to":[8,64,99,130,145,172,197,213],"observe":[9],"progression-free":[10],"survival":[11],"benefits":[12],"that":[13],"do":[14],"not":[15,185],"translate":[16],"into":[17],"comparable":[18],"OS":[19],"benefits.":[20],"exploratory":[22],"analyses,":[23],"we":[24],"examined":[25],"the":[26,42,54,65,73,85,126,147,237,280],"effect":[27],"of":[28,72,149,279,282],"slow":[29,150,174],"vs":[30,155,175,231],"fast":[31,156,176,232],"first-line":[32],"(1L)":[33],"TTP":[34,178,263,291,314,316],"on":[35,162],"ppOS":[36,163,223,229,269],"in":[37,40,125,179,217,236],"3":[38,51,94],"studies":[39],"NSCLC:":[41],"ECOG":[43],"4599":[44],"(E4599)":[45,101],"and":[46,53,75,89,183,224,292],"PointBreak":[47],"(PB)":[48,104],"randomized":[49,63],"phase":[50],"ARIES":[55,120,389],"observational":[56],"cohort":[57],"study":[58],"(OCS).":[59],"Methods:":[60],"Patients":[61],"(pts)":[62],"paclitaxel-carbopaltin":[66],"(PC)":[67,318],"+":[68],"bevacizumab":[69],"(BV)":[70],"arms":[71],"E4599":[74,246,317,341],"PB":[76,365],"trials":[77],"received":[78,108,249],"P":[79],"200":[80],"mg/m2,":[81],"C":[82],"area":[83],"under":[84],"curve":[86],"(AUC)":[87],"6,":[88],"BV":[90,110,134],"15":[91],"mg/kg":[92],"every":[93],"weeks":[95],"(q3w)":[96],"for":[97,215,228,245],"up":[98],"6":[100,153,159],"or":[102,116],"4":[103],"cycles.":[105],"Eligible":[106],"pts":[107,124,180,198,247,259],"maintenance":[109],"q3w":[111],"until":[112],"disease":[113],"progression":[114,161],"(PD)":[115],"unacceptable":[117],"toxicity.":[118],"The":[119],"OCS":[121],"prospectively":[122],"enrolled":[123],"US":[127],"from":[128],"2006":[129],"2009":[131],"receiving":[132],"1L":[133,177,194,205,250,265,276,290],"with":[135,264,271],"various":[136],"chemotherapy":[137],"(CT)":[138],"regimens.":[139],"Post":[140],"hoc":[141],"analyses":[142],"were":[143,211,241],"conducted":[144],"assess":[146],"association":[148],"(TTP":[151,157],"\u2265":[152],"mo)":[154,160],"<":[158],"within":[164,190],"treatment":[165,189],"groups.":[166],"A":[167],"landmark":[168],"analysis":[169],"was":[170],"used":[171,212],"compare":[173],"who":[181,199,248,260,273],"did":[182,184],"receive":[186],"second-line":[187],"(2L)":[188],"45":[191,202],"days":[192,203],"after":[193],"PD":[195],"(restricted":[196],"survived":[200],">":[201],"post":[204],"PD).":[206],"Cox":[207],"proportional":[208],"hazards":[209],"models":[210],"adjust":[214],"differences":[216],"pt":[218],"baseline":[219],"characteristics.":[220],"Results:":[221],"Median":[222,306],"hazard":[225],"ratios":[226],"(HRs)":[227],"(slow":[230],"TTP)":[233],"are":[234],"shown":[235],"table.":[238],"All":[239],"HRs":[240],"statistically":[242],"significant,":[243],"except":[244],"PC":[251],"but":[252],"no":[253],"2L":[254,283,304],"therapy.":[255,284],"Conclusions:":[256],"Advanced":[257],"NSCLC":[258],"experienced":[261,274],"longer":[262],"therapy":[266],"had":[267],"improved":[268],"compared":[270],"those":[272],"shorter":[275],"TTP,":[277],"regardless":[278],"receipt":[281],"Results":[285],"suggest":[286],"a":[287],"correlation":[288],"between":[289],"subsequent":[293],"OS.":[294],"Clinical":[295],"trial":[296],"information:":[297],"NCT00388206,":[298],"NCT00021060,":[299],"NCT00762034.":[300],"Study":[301],"(1L":[302],"Therapy)":[303],"Therapy":[305],"ppOS,":[307],"mo":[308],"HR":[309],"(95%":[310],"confidence":[311],"interval)":[312],"Slow":[313],"Fast":[315],"Yes":[319,343,367,391],"n":[320,324,331,335,344,348,355,359,368,372,379,383,392,396,403,407],"=":[321,325,332,336,345,349,356,360,369,373,380,384,393,397,404,408],"63":[322],"9.4":[323],"135":[326],"6.2":[327],"0.66":[328],"(0.47\u20130.93)":[329],"No":[330,354,378,402],"28":[333],"6.9":[334,399],"48":[337],"7.0":[338],"0.64":[339,400],"(0.37\u20131.10)":[340],"(PC-BV)":[342,366],"92":[346],"8.8":[347],"78":[350],"5.4":[351],"0.55":[352],"(0.39\u20130.77)":[353],"39":[357],"10.7":[358],"31":[361],"7.3":[362,375],"0.54":[363],"(0.31\u20130.94)":[364],"73":[370],"11.3":[371],"95":[374],"0.53":[376],"(0.36\u20130.77)":[377],"69":[381],"10.3":[382],"54":[385],"7.2":[386],"0.40":[387],"(0.26\u20130.63)":[388],"(CT-BV)":[390],"505":[394],"11.4":[395],"412":[398],"(0.56\u20130.75)":[401],"220":[405],"10.5":[406],"149":[409],"4.1":[410],"0.44":[411],"(0.34\u20130.56)":[412]},"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-04-25T00:00:00"}